C6K0 Stock Overview
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.95 |
| 52 Week High | US$960.00 |
| 52 Week Low | US$0.24 |
| Beta | 1.17 |
| 1 Month Change | 162.59% |
| 3 Month Change | 168.38% |
| 1 Year Change | -98.25% |
| 3 Year Change | -99.82% |
| 5 Year Change | -99.92% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| C6K0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -20.9% | -5.1% | -2.0% |
| 1Y | -98.2% | -21.1% | -0.3% |
Return vs Industry: C6K0 underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: C6K0 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| C6K0 volatility | |
|---|---|
| C6K0 Average Weekly Movement | 58.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C6K0's share price has been volatile over the past 3 months.
Volatility Over Time: C6K0's weekly volatility has increased from 52% to 59% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company’s drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn’s disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II.
Avalo Therapeutics, Inc. Fundamentals Summary
| C6K0 fundamental statistics | |
|---|---|
| Market cap | €11.29m |
| Earnings (TTM) | -€29.61m |
| Revenue (TTM) | €1.81m |
6.3x
P/S Ratio-0.4x
P/E RatioIs C6K0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C6K0 income statement (TTM) | |
|---|---|
| Revenue | US$1.92m |
| Cost of Revenue | US$9.95m |
| Gross Profit | -US$8.02m |
| Other Expenses | US$23.52m |
| Earnings | -US$31.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -30.50 |
| Gross Margin | -417.05% |
| Net Profit Margin | -1,639.50% |
| Debt/Equity Ratio | 0% |
How did C6K0 perform over the long term?
See historical performance and comparison